Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Heron Therapeutics reports strong sales growth and successful product launches

Heron Therapeutics showcased strong sales growth and successful product launches in Q4 2022.
While facing challenges such as delayed EU launch and regulatory concerns, the company is focused on strategic growth opportunities.
Opportunities to increase product uptake and drive market penetration through targeted strategies were discussed.
Overall, Heron Therapeutics remains optimistic about future updates and growth prospects.

Heron Therapeutics reports strong Q1 earnings amidst product challenges

Heron Therapeutics' Q1 2023 performance reflects revenue growth and a strategic focus on key products despite operational challenges.
The company's strengths in product innovation and market potential position it well for future growth opportunities.
Addressing challenges in product uptake and operational efficiency will be crucial for Heron Therapeutics to sustain its positive momentum.
By leveraging opportunities in product expansion and strategic realignment, the company can enhance profitability and drive long-term success.

Heron Therapeutics reports revenue growth and strategic financing for future

Heron Therapeutics delivered solid revenue growth in Q2 2023, driven by strong sales performance in its oncology portfolio and strategic financing activities.
While facing operating losses, the company remains focused on cost-saving initiatives, product growth, and maximizing asset value to drive future profitability.
Opportunities lie in upcoming product expansions, market acceptance of new launches, and strategic partnerships to fuel Heron Therapeutics' growth trajectory.
With a resilient financial position and a clear strategic direction, Heron Therapeutics is poised for future success in the competitive pharmaceutical landscape.

Heron Therapeutics cuts costs, boosts margins, eyes revenue growth

Heron Therapeutics demonstrated strong financial discipline with reduced operational expenses and improving gross margins. Record-high unit sales of key products and a clear commercial strategy position the company for revenue growth. While facing financial challenges and aiming for profitability, Heron Therapeutics remains optimistic about the growth potential of its key products.

Heron Therapeutics exceeds revenue expectations, eyes profitability by Q4 2024

Heron Therapeutics delivered robust financial results in Q4 2023, driven by strong oncology franchise performance and strategic partnerships. With a focus on innovation, cost efficiency, and revenue expansion, the company aims to achieve positive EBITDA by Q4 2024 and capitalize on market opportunities for sustained growth.

Heron Therapeutics excels in Q1, eyes profitability by 2024

Heron Therapeutics made notable progress in Q1 2024, with achievements in product performance, revenue growth, and profitability targets.
While facing challenges in EBITDA variability and regulatory compliance, the company is well-positioned to capitalize on growth opportunities.
By leveraging strengths in sales strategies, R&D focus, and financial efficiency, Heron Therapeutics aims for sustained success in the market.
Overall, the company's strategic initiatives and strong financial outlook signal a positive trajectory for future growth and market expansion.

Heron Therapeutics (HRTX) reports robust Q2 performance and strategic growth plans

Heron Therapeutics (HRTX) delivered strong financial performance with revenue growth, improved margins, and effective expense control in Q2 2024.
Despite challenges like potential competition and regulatory uncertainties, HRTX's strategic strengths in product portfolio and partnerships position it for future success.
Opportunities for growth through product expansions, partnerships, and expense management strategies highlight a positive outlook for HRTX in the competitive market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , Aug. 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report second quarter 2022 financial results and discuss recent business highlights.

Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Altimmune

Amylyx Pharmaceuticals

Arcutis Biotherapeutics

Axsome Therapeutics

bluebird bio

Intercept Pharma

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on InvestorPlace.

7 Biotech Stocks to Buy for Q3

Heron Therapeutics Inc. HRTX, +3.26% said Thursday it will lay off about one-third of its workforce as part of a restructuring expected to save $43 million a year. The biotechnology company's stock was still inactive in premarket trading.

Heron Therapeutics to cut about one-third of its workforce as part of cost-cutting plan

- Changes result in annualized cost savings of $43M, extending the cash runway; Company is continuing to reduce external spend -  - Reduces organization headcount by 34% - - Priorities remain on commercial growth for both the Acute Care and Oncology Care franchises - SAN DIEGO , June 30, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced a corporate restructuring and cost reduction plan to address the current market dynamics and prepare the company for long-term sustainability. The Company expects these actions will result in annualized cost savings of $43 million and will enable Heron to maintain a streamlined organization to support its acute care and oncology care franchises and extend its cash runway.

Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability

SAN DIEGO , June 14, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the online publication of a new study evaluating the efficacy and safety of ZYNRELEF (bupivacaine and meloxicam) extended-release solution as the foundation of a perioperative non-opioid multimodal analgesic (MMA) regimen in patients undergoing total knee arthroplasty (TKA). ZYNRELEF is approved by the U.S. Food and Drug Administration (FDA) for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty

SAN DIEGO , May 26, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that company management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 8:30 am ET.  The conference is taking place June 8-10 th, 2022 in New York, NY.

Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

NEW YORK , May 26, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Heron Therapeutics, Inc. (NASDAQ: HRTX). If you are a shareholder of Heron Therapeutics, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: http://pjlfirm.com/heron-therapeutics-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Heron Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

- New interim data from Phase 2 study suggests ZYNRELEF was well-tolerated and may effectively manage postpartum pain and minimize postoperative opioid use in women undergoing Caesarean sections - SAN DIEGO , May 16, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today presented at the Society for Obstetric Anesthesia and Perinatology (SOAP) 54th Annual Meeting results from a Phase 2 open-label, multi-cohort study evaluating interim safety and efficacy of ZYRNELEF (bupivacaine and meloxicam) extended-release solution administered postpartum to women undergoing a planned Caesarean section (C-section). ZYNRELEF is currently approved by the U.S. Food and Drug Administration (FDA) for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2022 Results Conference Call May 9, 2022 4:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - Chairman and CEO John Poyhonen - President and Chief Commercial Officer Kimberly Manhard - EVP, Drug Development and Board Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald Josh Schimmer - Evercore ISI Serge Belanger - Needham and Company Boris Peaker - Cowen Kelly Shi - Jefferies Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics First Quarter 2022 Earnings Conference.

Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q1 2022 Results - Earnings Call Transcript

- ZYNRELEF® unit demand increased 68% in the first quarter compared to the prior quarter - - Centers for Medicare and Medicaid Services approved a 3-year transitional pass-through status for ZYNRELEF beginning April 1, 2022 to support separate reimbursement outside of the surgical bundle payment for the HOPD setting of care - - Oncology Care Franchise net revenue of $22.4 million in Q1 2022, a 13% increase over the prior quarter - - Oncology Care Franchise full-year 2022 net revenue expected to be $89 million to $93 million – SAN DIEGO , May 9, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2022 and highlighted recent corporate updates. Recent Corporate Updates Acute Care Franchise ZYNRELEF: The ZYNRELEF (bupivacaine and meloxicam) extended-release solution New Drug Application (NDA) was approved by the U.S. Food and Drug Administration (FDA) in May 2021.

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates

SAN DIEGO , May 3, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Monday, May 9, 2022 at 4:30 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights.

Heron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022

SAN DIEGO , April 5, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that company management will participate in a fireside chat at the 21st Annual Virtual Needham Healthcare Conference on Monday, April 11, 2022 at 8:00 am PT/11:00 am ET. A live webcast of the fireside chat will be available on the Company's website at www.herontx.com in the Investor Resources section.

Heron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference

Heron has lost 60% of its value in less than a year, despite the company making some progress.

Heron Therapeutics: Cash Is A Problem Again

- ZYNRELEF is the only local anesthetic with separate reimbursement in both the Hospital Outpatient and Ambulatory Surgical Center settings of care - SAN DIEGO , March 25, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through status for ZYNRELEF (bupivacaine and meloxicam) extended-release solution, which will be established for three years beginning on April 1, 2022, for separate reimbursement outside of the surgical bundle payment in the Hospital Outpatient Department (HOPD) setting of care. This CMS approval makes ZYNRELEF the only local anesthetic with separate reimbursement in the hospital outpatient market.

Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care

- ZYNRELEF is the first and only extended-release local anesthetic approved by Health Canada - SAN DIEGO , March 17, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Health Canada has issued a Notice of Compliance (NOC) to commercialize ZYNRELEF (bupivacaine and meloxicam extended-release solution) for instillation into the surgical wound for postoperative analgesia after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures. Based on prior agreements with the U.S. Food and Drug Administration (FDA), Heron already has clinical studies underway, which we plan to submit to Health Canada to expand the indication statement.

Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain

Legend Biotech

Pieris Pharma

Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.

Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.

Heron Therapeutics had a productive 2021 with several corporate and commercial achievements that will set the company up for future growth.

Heron Therapeutics: Changing Strategy After Disappointing Earnings

SAN DIEGO, March 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that company management will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022 at 11:10 am PT/2:10 pm ET. A live webcast of the fireside chat will be available on the Company's website at www.herontx.com in the Investor Resources section.

Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference

The biotech's Q4 results didn't live up to expectations.

Why Heron Therapeutics Stock Is Getting Hammered Today

Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q4 2021 Results - Earnings Call Transcript

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 8.47% and 20.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q4 Loss, Lags Revenue Estimates

SAN DIEGO, Feb. 28, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted recent corporate updates. Recent Corporate Updates Acute Care Franchise ZYNRELEF:   The ZYNRELEF (bupivacaine and meloxicam) extended-release solution New Drug Application (NDA) was approved by the U.S. Food and Drug Administration (FDA) in May 2021.

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates

SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights.

Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Cassava Sciences Inc

As I pointed out in a previous discussion, short selling is not for the faint of heart and is probably best left to experienced traders. But there is an opportunity for investors to make money by keeping an eye on companies that could be subject to a short squeeze.

Are Herron Therapeutics, Cassava Sciences Ripe for a Short Squeeze?

The FDA grants label expansion to Heron???s (HRTX) Zynrelef for pain relief after small to medium abdominal surgeries, lower extremity total joint replacements, and foot and ankle surgeries in adults.

News for Heron Therapeutics Stock (HRTX)